Three-point technique of fat quantification of muscle tissue as a marker of disease progression in Duchenne muscular dystrophy: preliminary study.

OBJECTIVE Clinical trials involving patients with Duchenne muscular dystrophy are hindered by the lack of suitable objective end points. The purpose of this study was to examine whether muscle lipid infiltration measured with the three-point Dixon MRI technique has value as a marker of disease severity. SUBJECTS AND METHODS Disease severity in nine boys (mean age, 8.6 +/- 2.7 years) with Duchenne muscular dystrophy was determined with the functional ability scale of Brooke and associates. Functional scores were compared with strength measurements obtained by manual testing of muscles of the lower extremities, knee extensor strength measured with an isokinetic dynamometer, and muscle fat percentage in the quadriceps and hamstrings determined with the three-point Dixon MRI technique. RESULTS MRI measurements of fat infiltration had stronger correlation (p < 0.05) with functional grade than did measurements obtained with manual muscle testing (p = 0.07) or quantitative strength measured with the isokinetic dynamometer (p = 0.54). Muscle fat percentage did not correlate with strength measurements from manual or dynamometer muscle testing but increased with age in subjects with Duchenne muscular dystrophy. CONCLUSION Muscle adiposity values obtained with three-point Dixon MRI are accurate in assessment of disease severity in patients with Duchenne muscular dystrophy. Because they are not influenced by patient effort or examiner variability, these measurements are more objective and reproducible than measurements of muscle strength.

[1]  Vicente Gilsanz,et al.  Fat quantification using three-point dixon technique: in vitro validation. , 2005, Academic radiology.

[2]  R. Abresch,et al.  Serial manual muscle testing in Duchenne muscular dystrophy. , 1993, Archives of physical medicine and rehabilitation.

[3]  V. Dubowitz,et al.  Quantitation of muscle function in children: A prospective study in duchenne muscular dystrophy , 1982, Muscle & nerve.

[4]  Anita Beelen,et al.  Predictive Factors of Cessation of Ambulation in Patients with Duchenne Muscular Dystrophy , 2002, American journal of physical medicine & rehabilitation.

[5]  R. Adams,et al.  Diseases of Muscle: Pathological Foundations of Clinical Myology , 1985 .

[6]  G. Liu,et al.  Duchenne muscular dystrophy: MR grading system with functional correlation. , 1993, Radiology.

[7]  C. Reimers,et al.  Calf enlargement in neuromuscular diseases: a quantitative ultrasound study in 350 patients and review of the literature , 1996, Journal of the Neurological Sciences.

[8]  R. Abresch,et al.  Profiles of neuromuscular diseases. Becker's muscular dystrophy. , 1995, American journal of physical medicine & rehabilitation.

[9]  R. Abresch,et al.  Erratum: Profiles of neuromuscular diseases: Duchenne muscular dystrophy (American Journal of Physical Medicine and Rehabilitation (1995) 74 (S70- S92)) , 1996 .

[10]  N Roberts,et al.  Estimation of body composition in muscular dystrophy by MRI and stereology , 2000, Journal of Magnetic Resonance Imaging.

[11]  Akinori Nakamura,et al.  Evaluation of dystrophic dog pathology by fat‐suppressed T2‐weighted imaging , 2009, Muscle & nerve.

[12]  Yen-Mou Lu,et al.  Measurement of the Functional Status of Patients with Different Types of Muscular Dystrophy , 2009, The Kaohsiung journal of medical sciences.

[13]  J. Miller,et al.  Clinical investigation in duchenne dystrophy: 2. Determination of the “power” of therapeutic trials based on the natural history , 1983, Muscle & nerve.

[14]  Y. Tateno,et al.  Protron spin‐lattice relaxation time of duchenne dystrophy skeletal muscle by magnetic resonance imaging , 1988, Muscle & nerve.

[15]  M. Brooke,et al.  Clinical trial in duchenne dystrophy. I. The design of the protocol , 1981, Muscle & nerve.

[16]  H. Gruber,et al.  Neuromuscular diseases: evaluation with high-frequency sonography. , 1990 .

[17]  A. Connolly,et al.  Compositional analysis of muscle in boys with Duchenne muscular dystrophy using MR imaging , 2005, Skeletal Radiology.

[18]  K. Nayak,et al.  Change in the proton T1 of fat and water in mixture , 2010, Magnetic resonance in medicine.

[19]  G. Bentley,et al.  A randomized controlled trial of early surgery in duchenne muscular dystrophy , 1992, Neuromuscular Disorders.

[20]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.

[21]  F. Mastaglia,et al.  Morphological changes in dystrophic muscle. , 1980, British medical bulletin.

[22]  T. Khurana,et al.  Therapeutics for Duchenne muscular dystrophy: current approaches and future directions , 2004, Journal of Molecular Medicine.

[23]  M. Geffner,et al.  Obesity and fat quantification in lean tissues using three-point Dixon MR imaging , 2005, Pediatric Radiology.

[24]  S. Leeman,et al.  Quantitative Sonography of Muscle , 1989 .

[25]  S. Giannini,et al.  Upper limb bone mineral density and body composition measured by peripheral quantitative computed tomography in right-handed adults: The role of the dominance effect , 2009, Journal of endocrinological investigation.

[26]  Benjamin S. Aribisala,et al.  MR imaging in Duchenne muscular dystrophy: Quantification of T1‐weighted signal, contrast uptake, and the effects of exercise , 2009, Journal of magnetic resonance imaging : JMRI.

[27]  Walteil J. Murphy,et al.  MRI of normal and pathologic skeletal muscle. , 1986, AJR. American journal of roentgenology.

[28]  C. Dani,et al.  Enhancement of myogenic and muscle repair capacities of human adipose-derived stem cells with forced expression of MyoD. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  S. Zuberi,et al.  Muscle ultrasound in the assessment of suspected neuromuscular disease in childhood , 1999, Neuromuscular Disorders.

[30]  R. Kapsa,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Molecular Pathology of Dmd Novel Therapies for Dmd Novel Therapies for Duchenne Muscular Dystrophy , 2022 .

[31]  W. T. Dixon Simple proton spectroscopic imaging. , 1984, Radiology.

[32]  J. Tidball,et al.  Skipping to new gene therapies for muscular dystrophy , 2003, Nature Medicine.

[33]  Arend Heerschap,et al.  Quantitative MR imaging of individual muscle involvement in facioscapulohumeral muscular dystrophy , 2009, Neuromuscular Disorders.

[34]  I. Suramo,et al.  High‐frequency ultrasonography of skeletal muscle in children with neuromuscular disease. , 1988, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[35]  J. Miller,et al.  Duchenne muscular dystrophy , 1989, Neurology.